Recent research indicates that colon cancer patients with circulating tumor DNA post-surgery may improve their survival likelihood with daily celecoxib use. Celecoxib, a COX-2 inhibitor, significantly ...

Selective cyclo-oxygenase (COX)-2 inhibitors were developed with the ... Soon after their introduction into the market, the sales of celecoxib and rofecoxib went up considerably.

Patients with colon cancer who still have cancer cells in their blood after surgery may improve their survival odds with ...

The Food and Drug Administration announced Thursday its approval of suzetrigine, the first new painkiller greenlit by the ...

The CLASS study and other major cohort analyses suggest that celecoxib could be less hazardous ... of potential cardiovascular side effects of COX inhibitors and NSAIDs persists.

Although ctDNA positivity generally meant worse disease-free survival in stage 3 resected colon cancer, patients with ctDNA ...

The U.S. Food and Drug Administration (FDA) on Thursday approved Journavx, the first new class of pain medication in more ...

A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will ...

As gastroenterology research progresses, it is critical to comprehend the connection between stomach cancer and gastric ...

The drug, known as suzetrigine, is the first new painkiller approved in the U.S. since 1998. It can be used to relieve pain after surgery or injury, and some researchers say it might be the start of a ...

Below, check out the roundup of California Healthline's coverage. For today's national health news, read KFF Health News' Morning Briefing.

Who's ready to play Sara's new game? Get all the details here.